Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in progressive pulmonary fibrosis with eosinophilia
2022-003584-18Phase 2Active
- Sponsor
- Philipps-Universität Marburg
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis (PF), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) comparing Tezepelumab 210 mg Q4W with Placebo (2 arms). Primary endpoint: Change in peripheral blood cell count (absolute eosinophil numbers) at 24 weeks. Started Jan 2023; status: active.
02
Drugs
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-003584-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003584-18.